Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 148Biopsy 119pembrolizumab 90Carboplatin 81Cisplatin 74Nivolumab 72Cyclophosphamide 65Paclitaxel 61Gemcitabine 49Radiotherapy 47Bevacizumab 43Dexamethasone 39durvalumab 36venetoclax 34Fluorouracil 34atezolizumab 33Pemetrexed 32Injections 32Capecitabine 32Doxorubicin 31olaparib 30Rituximab 30Radiation 28Oxaliplatin 28Lenalidomide 28Prednisone 27Etoposide 27fludarabine 26X-Rays 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × luspatercept × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡